LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

Home・Akcijų sąrašas・MannKind Corp

MannKind Corp

Atidarymo kaina

SektoriusSveikatos priežiūra

3.71 1.92

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.54

Max

3.73

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-671K -17M
Pardavimai	-22M 90M
P/E Sektoriaus vid.	140.5 50.102
Pelnas, tenkantis vienai akcijai	-0.02
Pelno marža	-18.431
Darbuotojai	591
EBITDA	5.9M 3.4M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+114.93% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	177M 1B
Ankstesnė atidarymo kaina	1.79
Ankstesnė uždarymo kaina	3.71

Naujienos nuotaikos

By Acuity

67%

33%

295 / 344 reitingas Healthcare

MannKind Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-28 22:47; UTC

Uždarbis

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

2026-05-28 20:45; UTC

Uždarbis

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

2026-05-28 23:43; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

2026-05-28 23:39; UTC

Rinkos pokalbiai

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

2026-05-28 23:31; UTC

Rinkos pokalbiai

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

2026-05-28 23:17; UTC

Rinkos pokalbiai

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

2026-05-28 23:02; UTC

Rinkos pokalbiai

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

2026-05-28 22:41; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-28 22:41; UTC

Rinkos pokalbiai

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

2026-05-28 22:37; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

M&A-Related Insurance Payments In North America Rise -- Market Talk

2026-05-28 22:04; UTC

Įsigijimai, susijungimai, perėmimai

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

2026-05-28 22:04; UTC

Įsigijimai, susijungimai, perėmimai

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

2026-05-28 21:12; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

2026-05-28 21:00; UTC

Uždarbis

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

2026-05-28 20:57; UTC

Uždarbis

Dell Stock Soars on Blowout Earnings -- Barrons.com

2026-05-28 20:55; UTC

Uždarbis

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

2026-05-28 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-28 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-28 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-28 20:48; UTC

Karštos akcijos

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

2026-05-28 20:34; UTC

Uždarbis

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

2026-05-28 20:31; UTC

Uždarbis

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

2026-05-28 20:28; UTC

Uždarbis

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

2026-05-28 20:26; UTC

Uždarbis

Dell Stock Soars on Blowout Earnings -- Barrons.com

2026-05-28 20:20; UTC

Uždarbis

Costco 3Q Membership Fees $1.37B

2026-05-28 20:20; UTC

Uždarbis

Costco 3Q Net Sales $69.15B

2026-05-28 20:19; UTC

Uždarbis

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

2026-05-28 20:19; UTC

Uždarbis

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

2026-05-28 20:17; UTC

Uždarbis

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

2026-05-28 20:17; UTC

Uždarbis

Costco 3Q Same-Store Sales Up 9.8% >COST

Akcijų palyginimas

Kainos pokytis

MannKind Corp Prognozė

Kainos tikslas

By TipRanks

114.93% į viršų

12 mėnesių prognozė

Vidutinis 7.63 USD 114.93%

Aukščiausias 10 USD

Žemiausias 4.75 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines MannKind Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

Pirkti

Laikyti

Parduoti

Remiantis 6 analitikų, pateikusių MannKind Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

295 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.